Azora Therapeutics, Inc. (ADIL) Form 8-K — Nov 9, 2026
Azora Therapeutics (formerly Adial Pharmaceuticals; Nasdaq: AZR) appointed three new independent directors on November 3, 2026: Aida Habtezion (former Pfizer CMO), Paul Hastings (Nkarta CEO), and Thomas Soloway (T-knife CEO). Board committees were reconstituted, with Soloway chairing audit and Matthew Davidson becoming board chair as the board shrank to five members. The appointments coincide with the departure of four legacy Adial directors (Anderson, Claiborne, Gilliland, Schuyler), who resigned without disagreement following the company's June 2026 acquisition of Azora Therapeutics.
Key figures
- Shares Outstanding
- 14243129
- Board Size
- 5
- Preferred Converted
- 9,924.260 shares of Series A Preferred converted into 9,924,260 shares of Common Stock
- Preferred Remaining
- 3,006.341 shares of Series A Preferred outstanding
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.